1/3-Community Psychosis Risk Screening: An Instrument Development Study Supplement
1/3-Community Psychosis Risk Screening: An Instrument Development Study Supplement
批准号:
9675623
负责人:
LAUREN M ELLMAN
金额:
$5.23万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-09-01 至 2022-06-30
关键词:
AdolescentAlcohol or Other Drugs useAnxietyAreaAttenuatedAwardBaltimoreCannabisCatchment AreaChicagoClinicalCommunitiesDSM-VDataDevice or Instrument DevelopmentDimensionsDiseaseEarly DiagnosisFamily history ofFunctional disorderFundingIndividualInterviewInvestigationMental DepressionMental disordersOnset of illnessOutcomeParentsPhiladelphiaPopulationPopulation HeterogeneityPost-Traumatic Stress DisordersPrevalencePreventionPsychotic DisordersPublic HealthQuestionnairesRecording of previous eventsRiskRisk FactorsRuralSample SizeSamplingSchizophreniaScreening procedureSiteStressStructureStudentsSymptomsSyndromeTimeTrainingTraumaattenuated psychosis syndromebaseexperiencefollow-uphigh riskpre-doctoralprogramspsychosocialpsychotic symptomsrelating to nervous systemscreeningsuburbtoolwhite matteryoung adult
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Abstract of the Study “Community psychosis risk screening: An instrument development study”
The ongoing, funded parent study aims to develop a brief, valid screening questionnaire to identify individuals
at risk for psychosis in non-clinical populations across 3 large, community catchment areas with diverse
populations. This is a needed study, as the current screening tools for at-risk psychotic populations have been
validated only in clinical and/or treatment seeking samples, which are not likely to generalize beyond these
specialized settings. This project is administering 3 well-known psychosis risk screeners, as well as symptom-
based (e.g., depression, anxiety, etc.) and risk-factor based questionnaires (e.g., cannabis and other
substance use, a family history of major mental disorders, trauma history) to 12,000 adolescents/young adults
in local communities across 3 demographically diverse sites (the greater Philadelphia, Baltimore, and Chicago
areas, including neighboring rural/suburban areas). Based on established cut-off scores from the 3 psychosis
screeners, 2,000 subjects deemed as questionnaire higher risk (QHR; n=1,000) and questionnaire lower risk
(QLR; n=1,000) for psychosis (estimated sample sizes based on pilot data and anticipated loss to follow up)
will be invited to complete semi-structured interviews to determine clinical high risk (CHR) for psychosis status
based on the Structured Interview for Psychosis-Risk Syndromes (SIPS) and to assess current/past major
mental disorders based on the Structured Clinical Interview for DSM-5 (SCID-5). The SIPS psychosis-risk
persistence syndromes and the DSM-5 attenuated positive syndrome (both assessed with the SIPS 5.6) also
will be collected and will be examined in supplementary analyses. Based on preliminary data and conservative
estimates, we anticipate that 186 of the QHR group will be considered CHR for psychosis. The specific aims
are as follows: 1) to determine norms and prevalence rates of attenuated positive psychotic symptoms across
3 diverse, community catchment areas and 2) to develop a screening questionnaire, inclusive of both
symptom-based and risk factor-based questions, that is validated against the SIPS to identify those at CHR for
psychosis in the community. This is the first study in the U.S. to determine the rate of subthreshold psychotic
symptoms across diverse non-help seeking samples, which is essential for any investigation that uses
dimensional approaches to psychotic disorders. Further, this study will develop an essential screening tool that
will identify which individuals have the greatest need of follow-up with structured interviews in CHR studies or
clinical settings to determine psychosis-risk status. This tool is will be valuable given findings that those who
develop psychotic disorders often do not seek treatment until after the onset of the disorder, and that duration
of untreated psychosis is associated with more serious clinical outcomes. The funded study has the potential
for major contributions to the early detection and prevention of psychotic disorders.The proposed diversity
supplement will fit within this award by providing essential training and time for a predoctoral student, Arielle
Ered, to develop her program of investigating neural and psychosocial risk factors for psychosis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CAPER: Computerized Assessment of Psychosis Risk Supplement
-
批准号:10540475
-
项目类别:
-
资助金额:$2.36万
-
财政年份:2020
-
负责人:LAUREN M ELLMAN
-
依托单位:
CAPER: Computerized Assessment of Psychosis Risk
-
批准号:10361304
-
项目类别:
-
资助金额:$31.7万
-
财政年份:2020
-
负责人:LAUREN M ELLMAN
-
依托单位:
CAPER: Computerized Assessment of Psychosis Risk
-
批准号:10794659
-
项目类别:
-
资助金额:$2.54万
-
财政年份:2020
-
负责人:LAUREN M ELLMAN
-
依托单位:
CAPER: Computerized Assessment of Psychosis Risk
-
批准号:10569011
-
项目类别:
-
资助金额:$31.7万
-
财政年份:2020
-
负责人:LAUREN M ELLMAN
-
依托单位:
CAPER: Computerized Assessment of Psychosis Risk
-
批准号:9980111
-
项目类别:
-
资助金额:$31.7万
-
财政年份:2020
-
负责人:LAUREN M ELLMAN
-
依托单位:
Maternal Inflammation During Pregnancy: Clinical and Neurocognitive Outcomes in Adult Offspring
-
批准号:10600865
-
项目类别:
-
资助金额:$60.74万
-
财政年份:2019
-
负责人:LAUREN M ELLMAN
-
依托单位:
Maternal Inflammation During Pregnancy: Clinical and Neurocognitive Outcomes in Adult Offspring
-
批准号:10380812
-
项目类别:
-
资助金额:$62.32万
-
财政年份:2019
-
负责人:LAUREN M ELLMAN
-
依托单位:
1/3 Community Psychosis Risk Screening: An Instrument Development Study
-
批准号:10203788
-
项目类别:
-
资助金额:$31.73万
-
财政年份:2017
-
负责人:LAUREN M ELLMAN
-
依托单位:
Fetal exposure to maternal stress and inflammation: Effects on neurodevelopment
-
批准号:8297405
-
项目类别:
-
资助金额:$40.78万
-
财政年份:2012
-
负责人:LAUREN M ELLMAN
-
依托单位:
Fetal exposure to maternal stress and inflammation: Effects on neurodevelopment
-
批准号:8596852
-
项目类别:
-
资助金额:$45.33万
-
财政年份:2012
-
负责人:LAUREN M ELLMAN
-
依托单位:
Fetal exposure to maternal stress and inflammation: Effects on neurodevelopment
-
批准号:8443812
-
项目类别:
-
资助金额:$44.22万
-
财政年份:2012
-
负责人:LAUREN M ELLMAN
-
依托单位: